Holen Sie sich die Stockscreener-App
3.56
1.71%
0.06
Handel nachbörslich:
3.60
0.04
+1.12%
Schlusskurs vom Vortag:
$3.50
Offen:
$3.52
24-Stunden-Volumen:
1.33M
Relative Volume:
0.91
Marktkapitalisierung:
$350.95M
Einnahmen:
$775.09M
Nettoeinkommen (Verlust:
$-58.68M
KGV:
-26.85
EPS:
-0.1326
Netto-Cashflow:
$64.06M
1W Leistung:
-17.97%
1M Leistung:
-24.97%
6M Leistung:
-29.22%
1J Leistung:
-48.18%
1-Tages-Spanne:
$3.4612
$3.59
1-Wochen-Bereich:
$3.305
$4.00
52-Wochen-Spanne:
$3.305
$8.80
Goodrx Holdings Inc Stock (GDRX) Company Profile
Firmenname
Goodrx Holdings Inc
Sektor
Branche
Telefon
(855) 268-2822
Adresse
2701 OLYMPIC BOULEVARD, SANTA MONICA
Vergleichen Sie GDRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GDRX
Goodrx Holdings Inc
|
3.56 | 1.22B | 775.09M | -58.68M | 64.06M | -0.1326 |
|
VEEV
Veeva Systems Inc
|
279.18 | 45.01B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
69.63 | 11.53B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
64.02 | 11.58B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
89.27 | 8.04B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.35 | 6.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Goodrx Holdings Inc Stock (GDRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2024-12-04 | Eingeleitet | Mizuho | Neutral |
| 2024-08-09 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-05-23 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-05-16 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-03-25 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-03-01 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2024-01-02 | Herabstufung | BofA Securities | Buy → Underperform |
| 2023-08-10 | Hochstufung | DA Davidson | Neutral → Buy |
| 2023-07-31 | Hochstufung | TD Cowen | Market Perform → Outperform |
| 2022-12-01 | Eingeleitet | Citigroup | Buy |
| 2022-11-04 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-09-16 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2022-09-07 | Eingeleitet | Truist | Hold |
| 2022-08-12 | Eingeleitet | DA Davidson | Neutral |
| 2022-06-10 | Herabstufung | Goldman | Buy → Neutral |
| 2022-06-06 | Fortgesetzt | BofA Securities | Buy |
| 2022-06-01 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-05-10 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-05-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-05-10 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2022-05-10 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-04-11 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-04-07 | Eingeleitet | Guggenheim | Buy |
| 2022-04-01 | Fortgesetzt | Credit Suisse | Neutral |
| 2022-03-15 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-03-01 | Bestätigt | Barclays | Overweight |
| 2022-03-01 | Bestätigt | BofA Securities | Neutral |
| 2022-03-01 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-01 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2022-03-01 | Bestätigt | Evercore ISI | Outperform |
| 2022-03-01 | Bestätigt | Goldman | Buy |
| 2022-03-01 | Bestätigt | JP Morgan | Underweight |
| 2022-03-01 | Bestätigt | RBC Capital Mkts | Outperform |
| 2022-03-01 | Bestätigt | SVB Leerink | Outperform |
| 2022-01-07 | Eingeleitet | Goldman | Buy |
| 2021-12-21 | Eingeleitet | Stephens | Overweight |
| 2021-12-02 | Eingeleitet | Jefferies | Buy |
| 2021-08-31 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-08-13 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2021-05-28 | Eingeleitet | Robert W. Baird | Neutral |
| 2021-04-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2021-01-25 | Eingeleitet | Guggenheim | Buy |
| 2020-11-19 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-18 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-10-19 | Eingeleitet | Barclays | Equal Weight |
| 2020-10-19 | Eingeleitet | BofA Securities | Neutral |
| 2020-10-19 | Eingeleitet | Citigroup | Buy |
| 2020-10-19 | Eingeleitet | Cowen | Outperform |
| 2020-10-19 | Eingeleitet | Credit Suisse | Outperform |
| 2020-10-19 | Eingeleitet | Deutsche Bank | Hold |
| 2020-10-19 | Eingeleitet | Goldman | Neutral |
| 2020-10-19 | Eingeleitet | JP Morgan | Neutral |
| 2020-10-19 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-10-19 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2020-10-19 | Eingeleitet | SVB Leerink | Outperform |
| 2020-10-19 | Eingeleitet | UBS | Buy |
Alle ansehen
Goodrx Holdings Inc Aktie (GDRX) Neueste Nachrichten
GoodRx Earnings Call: Growth Amid Challenges - TipRanks
GoodRx Holdings, Inc. (NASDAQ:GDRX) Q2 2025 Earnings Call Transcript - Insider Monkey
UBS Keeps Hold Rating on GoodRx Holdings with $4.25 Target - AInvest
GoodRx stock price target lowered to $4.25 from $5.25 at UBS - Investing.com Australia
GoodRx Holdings Inc. (GDRX) PT Lowered to $4.25 at UBS - StreetInsider
Deutsche Bank Adjusts GoodRx Price Target to $6 From $8, Maintains Hold Rating - MarketScreener
Raymond James Downgrades GoodRx Holdings to Outperform From Strong Buy, Adjusts Price Target to $5 From $9 - MarketScreener
GoodRx Holdings: Buy Rating Maintained Despite Short-term Adjustments - AInvest
GoodRx Holdings Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
GoodRx Holdings Inc. stock chart pattern explainedVolume Confirmed Setup with Entry Confidence - Newser
Using AI based signals to follow GoodRx Holdings Inc.AI-Based Reversal Point Prediction Signal - Newser
Earnings visualization tools for GoodRx Holdings Inc.Weekly Market Direction and Sector Summary - Newser
How to integrate GoodRx Holdings Inc. into portfolio analysis toolsShort-Term AI-Based Stock Price Forecast - Newser
How GoodRx Holdings Inc. stock performs during market volatilityWealth Accumulation Outlook for Safe Investors - Newser
Statistical indicators supporting GoodRx Holdings Inc.’s strengthWeekly Return Plan for Conservative Traders - Newser
GoodRx downgraded to Outperform from Strong Buy at Raymond James - TipRanks
GoodRx stock downgraded by Raymond James on guidance cut after Rite Aid closures - Investing.com South Africa
Raymond James Downgrades GoodRx Holdings Inc. (GDRX) to Outperform - StreetInsider
Transcript : GoodRx Holdings, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
GoodRx stock falls as Morgan Stanley cuts price target on retail challenges By Investing.com - Investing.com South Africa
GoodRx stock falls as Morgan Stanley cuts price target on retail challenges - Investing.com Canada
Morgan Stanley Cuts Price Target on GoodRx Holdings to $5 From $6, Keeps Equalweight Rating - MarketScreener
Little Excitement Around GoodRx Holdings, Inc.'s (NASDAQ:GDRX) Revenues As Shares Take 28% Pounding - simplywall.st
GoodRx Holdings Inc. (GDRX) PT Lowered to $5 at Morgan Stanley - StreetInsider
Goldman Sachs lowers GoodRx stock price target on healthcare headwinds By Investing.com - Investing.com Australia
Goldman Sachs lowers GoodRx stock price target on healthcare headwinds - Investing.com India
Analysts Weigh In on GoodRx Holdings (GDRX) and Arcutis Biotherapeutics (ARQT) - AInvest
GoodRx Q2 Earnings Fall Short of Expectations with EPS at 4c - AInvest
Forecasting GoodRx Holdings Inc. price range with options dataTechnical Chart Summary for Momentum Stocks - Newser
GoodRx Holdings Inc. (GDRX) PT Lowered to $3.75 at Goldman Sachs - StreetInsider
GoodRx (NASDAQ:GDRX) Hits New 1-Year Low After Earnings Miss - Defense World
GoodRx Holdings Inc (GDRX) Q2 2025 Earnings Call Highlights: Str - GuruFocus
GoodRx Reports Steady Q2 2025 Financial Results - TipRanks
GoodRx Holdings, Inc. (GDRX) Q2 Earnings and Revenues Lag Estimates - MSN
Compared to Estimates, GoodRx (GDRX) Q2 Earnings: A Look at Key Metrics - MSN
Goodrx stock hits 52-week low at $3.67 By Investing.com - Investing.com South Africa
Goodrx stock hits 52-week low at $3.67 - Investing.com
GoodRx Misses Forecasts But Sees Growth Ahead In 2025 - Finimize
GoodRx Misses Targets But Pharma Unit Powers Growth - Finimize
Decoding GoodRx Holdings Inc (GDRX): A Strategic SWOT Insight - GuruFocus
GoodRx Holdings, Inc. Q2 Profit Increases, But Misses Estimates - Nasdaq
GoodRx Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Judge refuses to let Meta and Google off the hook in GoodRx health data sharing lawsuit - Class Action Lawsuits
Digital healthcare firm GoodRx Q2 revenue misses estimates - MarketScreener
GoodRx Holdings, Inc. (GDRX) Misses Q2 EPS by 1c - StreetInsider
GoodRx Q2 2025 Financial Results - TradingView
GoodRx Q2 2025: Pharma Division Soars 32% Despite Rite Aid Impact, Company Revises Growth Outlook - Stock Titan
What makes GoodRx Holdings Inc. stock price move sharplyRisk Balanced Picks for Safer Trading - Newser
What data driven models say about GoodRx Holdings Inc.’s futureAlgorithmic Prediction of Market Breakouts - Newser
GoodRx Holdings, Inc. (GDRX) Stock Analysis: Exploring a 40% Potential Upside and Market Positioning - DirectorsTalk Interviews
Earnings Chart Overlay Points to GoodRx Holdings Inc. UpsideWeekly Watchlist of High Movers Released - beatles.ru
Finanzdaten der Goodrx Holdings Inc-Aktie (GDRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
11.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):